For research use only. Not for therapeutic Use.
Yohimbine-13C,d3 (CAS: 1261254-59-4), a high-quality pharmaceutical research compound designed for advanced studies in neuropharmacology and erectile dysfunction research. As an isotopically labeled analog of Yohimbine, it offers enhanced stability and improved tracing capabilities. Yohimbine-13C,d3 is ideal for use in pharmacological and biochemical research, providing precise and reliable data for your studies. This high-purity compound ensures consistent results, aiding in the development of novel therapies for neuropharmacological conditions and sexual health. Trusted by leading laboratories, Yohimbine-13C,d3 is your go-to solution for cutting-edge neuropharmacological research. Unlock new possibilities in erectile dysfunction and neurological treatment with Yohimbine-13C,d3, where innovation meets reliability.
Catalog Number | S000126 |
CAS Number | 1261254-59-4 |
Molecular Formula | C2013CH23D3N2O3 |
Purity | ≥95% |
IUPAC Name | trideuterio(113C)methyl (1S,15R,18S,19R,20S)-18-hydroxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate |
InChI | InChI=1S/C21H26N2O3/c1-26-21(25)19-15-10-17-20-14(13-4-2-3-5-16(13)22-20)8-9-23(17)11-12(15)6-7-18(19)24/h2-5,12,15,17-19,22,24H,6-11H2,1H3/t12-,15-,17-,18-,19+/m0/s1/i1+1D3 |
InChIKey | BLGXFZZNTVWLAY-BRIZNRDQSA-N |
SMILES | [2H][13C]([2H])([2H])OC(=O)[C@H]1[C@H](CC[C@@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O |
Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Saeed SA, et al. Signaling mechanisms mediated by G-protein coupled receptors in human platelets. Acta Pharmacol Sin. 2004 Jul;25(7):887-892. [3]. Blanchard RJ, et al. Yohimbine potentiates active defensive responses to threatening stimuli in Swiss-Webster mice. Pharmacol Biochem Behav. 1993 Mar;44(3):673-681. [4]. Fuller BB, et al. Downregulation of tyrosinase activity in human melanocyte cell cultures by yohimbine. J Invest Dermatol. 2000 Feb;114(2):268-276. |